When was Destiny Pharma founded?

Destiny Pharma was founded in 1997 and raised its 1st funding round 11 years after it was founded.

Where is Destiny Pharma located?

Destiny Pharma is headquartered in Brighton, United Kingdom.

How many employees does Destiny Pharma have?

As of Mar 31, 2026, the latest employee count at Destiny Pharma is 10.

Is Destiny Pharma a funded company?

Destiny Pharma is a funded company, having raised a total of $6.96M across 8 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on Dec 09, 2008.

When was the latest funding round of Destiny Pharma?

Destiny Pharma's latest funding was a $***** Grant (prize money) round on Jul 12, 2022, with participation from 1 investor.

Where does Destiny Pharma rank among its competitors?

Destiny Pharma ranks 11th amongst 201 active competitors, of which 76 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Vedanta Biosciences, which secured an undisclosed amount in Feb, 2024.

Who are the top competitors of Destiny Pharma?

Destiny Pharma's top competitors include Spero Therapeutics, Vedanta Biosciences and Paratek Pharma. Among them, Vedanta Biosciences secured the most recent funding round in February, 2024.

Destiny Pharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of drugs for the treatment of infectious diseases. It has proprietary XF platform to develop microbiome-based biotherapeutics including XF-73 Nasal to prevent post-surgical infections XF-73 dermal for skin infections, and SPOR-COV for COVID -19.

Website: destinypharma.com
Social

Key Metrics

Founded Year

1997

Location

Brighton, United Kingdom

Stage

Public

Total Funding

$6.96M in 8 rounds

Latest Funding Round

Grant (prize money), Jul 12, 2022, $*****

Investors

Longbow Capital & 14 more

Ranked

11^th among 201 active competitors

Employee Count

10 as on Mar 31, 2026

Similar Companies

Spero Therapeutics & 253 more

Exit Details

Public

View Destiny Pharma's full profile

Destiny Pharma is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
DESTINY CONSULTANTS LIMITED CIN: 9906553 , United Kingdom, Active	Dec 07, 2015	-	1 (As on Dec 31, 2021)
DESTINY PHARMA PLC CIN: 3167025 , Germany, Active	Mar 03, 1996	-	23 (As on Dec 31, 2022)

Destiny Pharma got listed on Sep 04, 2017.

Click here to take a look at Destiny Pharma's IPO in detail

Destiny Pharma has raised a total funding of $6.96M over 8 rounds. Its first funding round was on Dec 09, 2008. Its latest funding round was a Grant (prize money) round on Jul 12, 2022 for $*****. 1 investor participated in its latest round. Destiny Pharma has 15 institutional investors.

Here is the list of recent funding rounds of Destiny Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 12, 2022	9376021	Grant (prize money)	9382121	8945396	7540817	5687537
Nov 10, 2020	3835035	Post IPO	9478010	3051448	2497204	FinnCap & 1 more
Sep 07, 2020	6315250	Grant (prize money)	1269750	4051393	7871444	Gov

Access funding benchmarks and valuations. Sign up today!

View details of Destiny Pharma's funding rounds and investors

The founders of Destiny Pharma is William Love.

Here are the details of Destiny Pharma's key team members:

William Love: Founder of Destiny Pharma.
Contact Info: 1 email address

View details of Destiny Pharma's Founder profiles and Board Members

Destiny Pharma's employee count trend

Destiny Pharma has 10 employees as of Mar 26. Here is Destiny Pharma's employee count trend over the years:

Uncover Destiny Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Destiny Pharma include Spero Therapeutics, Vedanta Biosciences and Paratek Pharma. Here is the list of Top 10 competitors of Destiny Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Partners Health Care Innovation, Atlas Venture ... & 16 others	72/100
2nd	Vedanta Biosciences 2010, Cambridge (United States), Series E	Developer of therapeutics to treat infectious diseases	$350M	Invesco, Seventure Partners & 38 others	65/100
3rd	Paratek Pharma 1996, Boston (United States), Acquired	Developer of therapeutics for antimicrobial resistant infections	$96.5M	Aisling Capital, Phase4 Partners & 23 others	64/100
4th	Melinta Therapeutics 2000, Morristown (United States), Acquired	Developer of therapeutics for antibiotic-resistant infections	$186M	Warburg Pincus, SR One & 16 others	62/100
5th	Aelin Therapeutics 2017, Leuven (Belgium), Series A	Developer of antibiotics based on protein aggregation approach	$31.8M	Life Sciences Partners, Boehringer Ingelheim Venture Fund ... & 5 others	61/100
6th	Everest Medicines 2017, New York City (United States), Public	Developer of drugs for the treatment of cancer	$313M	RA Capital Management, Janchor Partners & 12 others	61/100
7th	Cubist Pharmaceuticals 1993, Lexington (United States), Acquired	Developing drugs to treat a range of acute care related diseases	-	Vivo Capital, Cardinal Partners & 2 others	61/100
8th	Bioversys 2008, Basel (Switzerland), Public	Developer of therapeutics for Antimicrobial Resistance	$62.5M	AMR Action Fund, Wellcome Trust & 10 others	60/100
9th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Viking Global Investors, Artis Ventures & 13 others	60/100
10th	ABAC Therapeutics 2014, Barcelona (Spain), Acquired	Early stage biopharma developing precision drugs for MDR bacterial infections	$19.8M	Pontifax, Global Health Investment Fund & 7 others	60/100
11th	Destiny Pharma 1997, Brighton (United Kingdom), Public	Developer of drugs for the treatment of infectious diseases	$6.96M	BioScience Managers, Rosetta Capital & 13 others	56/100